Loading the records…
Loading the records…
BILL ANALYSIS
HR10628 (Biosimilars Access and Affordability Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
neutral
Market Sentiment
4/10
Impact Score
1
Sectors Impacted
Early-stage bill with bipartisan support could accelerate biosimilar access to Medicare negotiation.
Pure-play biosimilar companies ($CHRS, $VTRS) are potential beneficiaries; originator biologic makers ($AMGN) face headwinds.
No funding authorized; impact depends on final legislative language and passage timeline.
The bill is too early to drive market moves, but the bipartisan sponsorship signals potential momentum. Investors in biosimilar-focused companies may see long-term tailwinds if the bill advances. Originator biologic stocks could face overhang from accelerated competition risk.
| Metric | Value |
|---|---|
| Bill Number | HR10628 |
| Market Sentiment | neutral |
| Event Date | |
| Affected Sectors | Healthcare |
| Source | View on Congress.gov → |
The Biosimilars Access and Affordability Act (HR10628) was introduced on September 28, 2026, and referred to the Energy and Commerce and Ways and Means Committees. It proposes technical changes to the timing of when biosimilar biological products become eligible for Medicare price negotiations under the Inflation Reduction Act. The bill is in early stages with bipartisan cosponsorship, and its impact on pharmaceutical companies depends on final language and passage.
Free — no credit card
HillSignal scores every bill, federal contract, and insider filing for market impact and emails you the high-conviction ones. Free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
© 2026 HillSignal. All rights reserved.
Not financial advice. For informational purposes only.